Neurocrine Biosciences Inc
NBIXNeurocrine Biosciences Inc (NBIX) is a biopharmaceutical company focused on the development and commercialization of treatments for neurological and endocrine disorders. Founded in 1992, the company specializes in innovative therapies for conditions such as Parkinson's disease, Tourette syndrome, and endometriosis, leveraging expertise in neuroscience and endocrine biology.
Company News
Connecticut-based fund Braidwell established a new $50.8 million stake in Acadia Pharmaceuticals, representing 2.1% of its reportable U.S. equity assets, as the company shows strong quarterly performance and potential for growth in neurological disorder treatments.
Nxera Pharma reported increased revenues from PIVLAZ® and QUVIVIQ® in Japan, progress in partnered programs including Neurocrine's Phase 3 trial, and launched a new proprietary pipeline targeting obesity and weight management.
Neurocrine Biosciences has amended its agreement with Takeda Pharmaceutical to obtain exclusive global rights to develop and commercialize the depression drug osavampator, except in Japan where Takeda will reacquire exclusive rights.
Sector ETF report for PBE
